Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET study of [11C]AZ14132516 in healthy participants
NCT05818514Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [11C]AZ14132516 in Crohn's disease (2 arms), sponsored by AstraZeneca. Primary endpoint: Standard Uptake Value and Standard Uptake Value Ratio. Started Apr 2023; status: completed.
02
Drugs
[11C]AZ14132516
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05818514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05818514.